This is a summary of the European Public Assessment Report (EPAR) for Tepadina. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tepadina.
Therapeutic Indication
### Therapeutic indication TEPADINA is indicated, in combination with other chemotherapy medicinal products: \- with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; \- when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
Therapeutic Area (MeSH)
N/AATC Code
L01AC01
ATC Item
thiotepa
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| thiotepa | N/A | 塞替派 |
EMA Name
Tepadina
Medicine Name
Tepadina
Aliases
N/ANo risk management plan link.
